U.S. Markets closed

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
1.39-0.01 (-0.71%)
At close: 3:54PM EDT

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1

Full Time Employees28

Key Executives

Mr. Donald J. McCaffreyCo-Founder, Chairman, Pres, CEO & Sec.676.24kN/AN/A
Mr. Aaron Bradley Cann CA, CPA, CBVChief Financial Officer322.97kN/AN/A
Mr. Kenneth Eugene Lebioda BASr. VP of Bus. & Corp. Devel.304.62kN/AN/A
Dr. Jan O. Johansson M.D., Ph.D.Sr. VP of Medical Affairs315.72kN/AN/A
Dr. Michael Sweeney M.D.Sr. VP of Clinical Devel.628.59kN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Resverlogix Corp., an epigenetics company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibition in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.